---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290861678.md"
description: "PRF Technologies shares are trading higher after the company announced expanded results from its preclinical study directly comparing its lead product candidate, PRF-110, to approved ZYNRELEF."
datetime: "2026-06-25T16:42:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290861678.md)
  - [en](https://longbridge.com/en/news/290861678.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290861678.md)
generator: "portal-rs"
---

# 

PRF Technologies shares are trading higher after the company announced expanded results from its preclinical study directly comparing its lead product candidate, PRF-110, to approved ZYNRELEF.

### Related Stocks

- [PRFX.US](https://longbridge.com/en/quote/PRFX.US.md)

## Related News & Research

- [PRF Technologies announces unregistered standby equity deal for up to $15 million shares with Yorkville](https://longbridge.com/en/news/290243404.md)
- [EXCLUSIVE: PRF Technologies Advances Drop-Less Drug For Cataract Surgery Pain](https://longbridge.com/en/news/284380452.md)
- [PRF Technologies reports expanded preclinical head-to-head data for PRF-110 vs Zynrelef in porcine pain model](https://longbridge.com/en/news/290832015.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**